Exjade-Early-Trial

Myelodysplastic Syndromes Clinical Trial

Official title:

Early Treatment With Deferasirox (Exjade®) in Low Risk MDS - a Prospective Multicentre Single-arm Single-stage Phase II Study -

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01058369
• Other study ID #: CICL670ADE06T
• Status: Terminated
• Phase: Phase 2
• Start date: April 2010
• Est. completion date: January 2013

Study information

• Verified date: September 2020
• Source: University of Erlangen-Nürnberg Medical School
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study outline: Deferasirox (Exjade®) is regularly used in severe iron overload in order to avoid organ damage of liver, heart and other organs. It has been proposed, that iron overload may not only impose damage to other organs but also to the bone marrow and thus worsen hematopoietic insufficiency in patients with MDS. Patients presenting with low or INT-1 risk MDS with only mild iron overload will be treated with deferasirox in this study. It will be analyzed if hematological improvement can be observed during this treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: January 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• MDS of subtype RA, RARS, RCMD, RCMD-RS (i.e. lower risk)

• RAEB I allowed, if clinically stable for > 3 months

• 5q-minus syndrome allowed, if lenalidomide unsuccessful or unavailable at the time of inclusion

• IPSS score < intermediate-1

• transfusion dependent or Hb < 10,5 g/dl

• History of less than 20 units of red blood cell transfusions or 100mL/kg of prepacked red blood cells (PRBCs), except for transfusions for acute bleeding

• Serum ferritin > 300 µg/l and < 1500 µg/l. This level should have been verified at least at two occasions within 3 months. Samples must be obtained in the absence of concomitant severe infection

• no indication for EPO (due to high endogenous EPO levels) or EPO without benefit in the past

• no indication and/or no plans for cytostatic drugs

• no previous exposure to cytostatic drugs, thalidomide, lenalidomide, G-CSF or EPO or exposure to any of these drugs has been terminated since > 8 weeks (4 weeks for G-CSF).

• no indication and/or no plans for stem cell transplantation

• stable or worsening cytopenia during the past 8 weeks. If in doubt, extend screening period to >= 8 weeks

• Patients of either gender and age > 18 years

• Life expectancy > 12 months

• Females of childbearing potential must use double-barrier contraception (for example orale contraception and condom).

• Mental ability of the patient to understand explications concerning the study and to understand and follow instructions of the investigating physician

• Written informed consent by the patient

Exclusion Criteria:

• Treatment with deferasirox or other chelation therapy for periods > 4 weeks before study start

• Patients with intolerance to Deferasirox

• Patients with a concomitant second malignant disease, possibly interfering with life expectancy

• Patients with mean levels of alanine aminotransferase (ALT) > 5x ULN

• Patients with uncontrolled systemic hypertension

• Patients with serum creatinine > 1.5x the upper limit of normal (ULN) or a creatinine clearance < 60 ml/min according to the MDRD formula (Levey 2005)

• History of nephrotic syndrome

• Systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent the patient from undergoing study treatment

• Patients with psychiatric or addictive disorders which prevent them from giving their informed consent or undergoing study treatment

• Patients treated with systemic investigational drugs within the past 4 weeks or topical investigational drug within the past 7 days

• Any other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following:

• history of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding;

• history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;

• history of pancreatic injury or pancreatitis; indications of impaired pancreatic function/injury as indicated by abnormal lipase or amylase;

• history of urinary obstruction or difficulty in voiding

• History of non-compliance to medical regimens and patients who are considered potentially unreliable and/or not cooperative

• History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by laboratory assays conducted during the screening period

• Patients with active uncontrolled infectious disease

• Pregnancy or breast feeding

• QT > 470 msec on screening ECG

• Patients with a history of Torsades de Pointes

Related Conditions & MeSH terms

• Myelodysplastic Syndromes

Intervention

Drug:
• Deferasirox (Novartis Pharma)
Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol

Locations

Country	Name	City	State
Germany	Medizinische Klinik 5, Universitätsklinikum Erlangen	Erlangen	Bavaria

Sponsors (2)

Lead Sponsor	Collaborator
University of Erlangen-Nürnberg Medical School	Novartis Pharmaceuticals

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fraction of Patients With Hematologic Improvement According to Modified IWG Criteria (Reduction of Transfusions and/or Increase in Hb, Improvement of Neutropenia and Thrombocytopenia)		within two years
Secondary	Evaluate the Safety and Tolerability Profile of Deferasirox in MDS Patients		within two years
Secondary	Effectiveness of Iron Depletion		within two years
Secondary	Correlation Between Hematological Improvement and Effectiveness of Iron Depletion		two years
Secondary	Development of Bone Marrow Morphology		two years
Secondary	Correlation Between Hematological Improvement and Pretreatment Parameters. Extension of This Analysis to MDS Patients on Deferasirox Within the Licensed Indication (More Severe Iron Overload)		two years
Secondary	Overall Survival		within two years
Secondary	AML-free Survival		within two years